Investors and payers sometimes balk at drugs approved on an accelerated pathway. Here’s how pharma can de-risk these ...

After incubating about 1,200 companies, the pharma giant is putting less emphasis on physical lab space — and taking a more ...

The investor narrative around Eli Lilly is deeply rooted in obesity. The blockbuster GLP-1 medications Mounjaro and Zepbound are driving the large pharma’s gains in revenue, which rose 39% ...

Parexel’s Stacy Hurt draws on her experience with chemotherapy and as a caregiver to spot patient burdens that AI-assisted ...

Pharmaceuticals enable modern healthcare by helping to prevent, manage, and cure disease, but growing demand is increasing their impact on the environment. For oral drug delivery, medicines must be ...

The dreaded patent cliff is fast approaching for Merck’s flagship blockbuster, but the deck might be stacked against its ...

As the industry donates and lobbies in both political directions, ongoing drug policy issues and a new head of PhRMA could ...

The biopharma industry doesn’t have a technology problem, it has an implementation problem . Over the last few years, digital transformation has become one of the most widely di ...

This is the second installment of a two-part series previewing pharma’s year ahead. Our first part examines how industry leaders see the financial market taking shape in 2024. It’s an exciting time to ...

Novo failed to prove that Lilly’s campaign — which featured claims of obesity drug superiority — meaningfully harmed the ...